Genetically modified stem cells to treat joint pain and inflammation
Official title: Autonomous RUNX2 suppression in genetically modified stem cell-derived chondrocytes as a disease modifying therapeutic for PTOA
Funded at University of Michigan at Ann Arbor · NIH-10799578 · Data updated 2026-11-12
This study is exploring how specially modified stem cells can help reduce joint pain and swelling for people with post-traumatic osteoarthritis by promoting healing and improving cartilage health.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | March 3, 2023 |
| Project end | January 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $157,946 |
| NIH project number | 5R21AR082016-02 |
| Project ID | NIH-10799578 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from post-traumatic osteoarthritis, particularly those experiencing significant joint pain and inflammation.
✕Less likely to help
Patients with non-traumatic osteoarthritis or those whose joint issues are unrelated to inflammation may not benefit from this research.
What this research studies
This research investigates the use of genetically engineered stem cells to address joint pain and inflammation associated with post-traumatic osteoarthritis (PTOA). The approach involves modifying mesenchymal stem cells to suppress a specific factor, RUNX2, which contributes to cartilage degradation and inflammation. By doing so, the researchers aim to enhance the regenerative potential of these cells and reduce inflammation in the joint environment. The study will evaluate the effectiveness of these modified cells in promoting cartilage formation and alleviating symptoms in affected patients.
Why it matters
Potential benefit: If successful, this research could lead to a novel treatment that significantly improves joint health and reduces pain for patients with PTOA.
How similar studies have gone: Previous research has shown promise in using genetically modified stem cells for joint repair, indicating potential success for this novel approach.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Coleman, Rhima — University of Michigan at Ann Arbor
- Study coordinator: Coleman, Rhima
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.